Insulet (NASDAQ:PODD) Given New $172.00 Price Target at Wells Fargo & Company

Insulet (NASDAQ:PODD) had its target price hoisted by equities researchers at Wells Fargo & Company from $144.00 to $172.00 in a research note issued on Thursday, Benzinga reports. The firm currently has an “equal weight” rating on the medical instruments supplier’s stock. Wells Fargo & Company‘s price target indicates a potential upside of 5.64% from the stock’s previous close.

A number of other equities analysts also recently weighed in on the company. Canaccord Genuity Group dropped their target price on Insulet from $249.00 to $179.00 and set a “buy” rating on the stock in a report on Thursday, August 6th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Insulet in a research report on Monday, September 21st. Barclays raised shares of Insulet to a “hold” rating in a research report on Wednesday, October 7th. Jefferies Financial Group reiterated a “buy” rating and issued a $200.00 price objective on shares of Insulet in a research note on Wednesday. Finally, Sanford C. Bernstein cut their target price on shares of Insulet from $200.00 to $175.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Thirteen equities research analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $188.20.

Insulet Stock Down 1.3%

Shares of PODD stock traded down $2.20 on Thursday, reaching $162.82. 59,780 shares of the company’s stock traded hands, compared to its average volume of 1,391,950. Insulet has a 12-month low of $126.40 and a 12-month high of $354.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 2.48. The company has a market capitalization of $11.29 billion, a P/E ratio of 30.51, a price-to-earnings-growth ratio of 1.22 and a beta of 1.06. The business’s 50 day moving average price is $141.65 and its two-hundred day moving average price is $178.00.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.59 by $0.40. Insulet had a return on equity of 29.29% and a net margin of 12.29%. The firm had revenue of $842.00 million during the quarter, compared to the consensus estimate of $832.63 million. During the same period in the prior year, the business earned $1.24 EPS. The business’s revenue for the quarter was up 19.2% on a year-over-year basis. On average, equities analysts forecast that Insulet will post 6.51 earnings per share for the current year.

Institutional Investors Weigh In On Insulet

Hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. bought a new stake in shares of Insulet in the 2nd quarter worth approximately $1,018,582,000. Arrowstreet Capital Limited Partnership grew its holdings in shares of Insulet by 462.7% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier’s stock worth $258,088,000 after purchasing an additional 1,011,369 shares in the last quarter. Man Group plc acquired a new stake in shares of Insulet during the 2nd quarter worth approximately $78,746,000. Amundi increased its position in shares of Insulet by 13.6% during the second quarter. Amundi now owns 507,847 shares of the medical instruments supplier’s stock valued at $77,320,000 after purchasing an additional 60,929 shares during the period. Finally, Bank of America Corp DE bought a new stake in shares of Insulet during the second quarter valued at approximately $64,921,000.

Insulet News Summary

Here are the key news stories impacting Insulet this week:

• Positive Sentiment: Q3 adjusted earnings were $1.99 per share, above the $1.59 consensus estimate, while revenue rose 19.2% year over year to $842 million, also exceeding expectations. The earnings call highlighted growth and margin expansion. Insulet Reports Strong Third-Quarter Growth and Margin Expansion
• Positive Sentiment: Insulet announced a $1 billion share-buyback authorization, which may support shareholder returns and signals confidence in the business. Insulet announces a $1 billion equity buyback
• Positive Sentiment: Reports said the company raised its 2026 outlook; one account noted the full-year EPS outlook was maintained. CEO sees slower growth in 2027 Insulet Q3 earnings and 2026 EPS outlook
• Negative Sentiment: Management expects growth to slow in 2027 and said rivals could take some share from Omnipod, raising concerns about the company’s future growth trajectory. CEO sees slower growth in 2027 and competition

About Insulet

Insulet Corporation is a medical device company that develops, manufactures and sells wearable, tubeless insulin delivery systems for people with insulin-dependent diabetes. Its products are designed to provide an alternative to traditional insulin injections and conventional tubed insulin pumps.

The company’s primary product platform is Omnipod, which includes the disposable, wearable Pod and a handheld controller or compatible smartphone-based application. Omnipod products include the Omnipod DASH system and the Omnipod 5 Automated Insulin Delivery System, which is designed to integrate with compatible continuous glucose monitoring technology to help automate insulin delivery.